TIG has entered into an agreement with its academic partners, the Catholic University Leuven (KULeuven) and Ghent University (UGent), the Dutch company Therosteon and a consortium of investors for the creation of a new small molecule drug development company, Arcarios Read more…
The blended valuation model implies a pricing of $4.40 given the fully diluted shares outstanding. The Sum of the Parts estimation of $5.62 is discounted 10% and is significantly above this stocks current price of $1.49. Read more…
Optimism is the systematic tendency for people to be overly confident about the outcome of a potential event(s) but, have we forgotten the … what else(s).
Net loss for Q2/10 was $2.3 M or $0.06 per share on weighted average outstanding of 37.6 M common shares. Read more…
STEM reported net loss of $4.61 M, or $0.04 per share. Read more…
Net loss for Q/2/10 was $3.1M or $0.16 per share. Read more…
OPXA’s Q2/10 net loss was $1.82 M or ($0.12) per share. Read more…
CYTX’s net loss was $5.4 M and $0.12 per share Read more…
The financial markets have thoroughly depreciated the stem cell universe but, many struggling stem cell companies are getting second, third and fourth chances Read more…
After a big rally in July, investors could be in for another bout of economic jitters this week as the focus shifts from earnings to the weak job market. Read more…
Founder and Director of Research, Henry McCusker enters his eighth (8) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.